Ikonisys SA stock analysis
Want to see FR:ALIKO full AI Analyst Report?
Ikonisys SA (ALIKO) Stock Price & Analysis
ALIKO Stock Chart & Stats
- Day’s Range
- EUR 1.41 - EUR 1.41
- 52-Week Range
- EUR 1.30 - EUR 1.84
- Previous Close
- EUR 1.41
- Volume
- N/A
- Average Volume (3M)
- 1,966
- Market Cap
- EUR 22.26M
- Enterprise Value
- EUR 24.43M
- Total Cash (Recent Filing)
- EUR 25.08K
- Total Debt (Recent Filing)
- EUR 4.13M
- Price to Earnings (P/E)
- ―
- Beta
- 0.21
- Next Earnings
- Oct 22, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth
The sharp revenue acceleration indicates improving customer adoption and commercial traction. Sustained growth could expand the installed base and increase future consumables and service revenue, supporting a more scalable recurring-revenue model.
Solid Gross Margin
A gross margin near 65% suggests the platform, reagent, and diagnostic workflow economics can support attractive contribution margins. If revenue growth continues, this gross-profit base may provide operating leverage once spending becomes more disciplined.
Improving Balance Sheet Leverage
Lower leverage and substantial equity relative to debt reduce immediate solvency pressure and provide greater financial flexibility. This gives the company more time to commercialize its products and pursue growth without excessive debt burdens.
Bears Say
Large Persistent Losses
Revenue growth has not yet translated into operating leverage. Very large, widening losses indicate that fixed costs, development spending, or commercialization expenses remain disproportionate to sales, limiting the credibility of near-term profitability.
Ongoing Cash Burn
Persistent negative operating and free cash flow means the business does not currently fund its own operations. Continued investment and commercialization therefore remain dependent on external financing, which can constrain execution and dilute shareholders.
Negative Return On Equity
Negative return on equity shows that the sizable equity base is not currently generating profits. If losses continue, retained deficits could gradually erode capital and reduce the balance-sheet cushion that currently offsets the low debt burden.
Ikonisys SA News
ALIKO FAQ
What was Ikonisys SA’s price range in the past 12 months?
What is Ikonisys SA’s market cap?
When is Ikonisys SA’s upcoming earnings report date?
How were Ikonisys SA’s earnings last quarter?
Is Ikonisys SA overvalued?
Does Ikonisys SA pay dividends?
What is Ikonisys SA’s EPS estimate?
How many shares outstanding does Ikonisys SA have?
What happened to Ikonisys SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Ikonisys SA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Ikonisys SA
Based in Paris, France, Ikonisys S.A. is a company specializing in cell-based diagnostics. It develops, produces, and commercializes medical diagnostic solutions for various cancers across the United States and Europe. Their core offering includes the Ikoniscope Robotic Microscope, which automates slide manipulation, scanning, and real-time image acquisition and analysis, thereby minimizing human error during diagnostic testing. The company provides a suite of specialized oncoFISH microscopy applications for cancer detection and characterization, such as oncoFISH bladder for analyzing urine samples, oncoFISH her2 for determining HER2 status in breast tissue biopsies, oncoFISH ALK for identifying rearrangements of the ALK gene, and oncoFISH PTEN for detecting PTEN gene deletions in prostate tissue biopsies. Ikonisys also offers tools for characterizing individual circulating tumor cells (CTCs) and analyzing circulating tumor DNA (ctDNA) to provide comprehensive tumor genotype information. Additionally, their Ikonisoft explorer software suite features dedicated FISH scanning applications: Ikonisoft explorer CS for cell suspensions on slides, and Ikonisoft explorer tissue for examining hybridized tissue sections. Finally, the IkoniWAN Gateway provides a secure, validated remote access solution for their Ikoniscope digital microscopy platforms.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Francesco Trisolini
- Employees
- 15
- Website
- www.ikonisys.com
- Address
- 62 Rue De Caumartin, Paris, IF, 75009, FR
Ikonisys SA (ALIKO) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 6 | 7 |
| Technical Analysis | 2 | 6 | 1 |
| Moving Averages | 6 | 0 | 6 |








